Patents by Inventor Julianty Angsana

Julianty Angsana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MATERIALS AND METHODS FOR MONITORING INFLAMMATION
    Publication number: 20230014092
    Abstract: A method of identifying a subject who is likely to be responsive to a treatment comprising an inhibitor of IL1?, or predicting the responsiveness of a subject to a treatment comprising an inhibitor of IL1?, comprising providing a sample from a subject; administering the inhibitor of IL1? to the sample; measuring levels of one or more biomarkers in the sample; and determining the pharmacodynamic or the pharmacokinetic effect of the inhibitor of IL1? based on the levels of the one or more biomarkers.
    Type: Application
    Filed: December 11, 2020
    Publication date: January 19, 2023
    Inventors: Ernesto MUNOZ, Julianty ANGSANA, Carl MANTHEY, Xuejun LIU
  • Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
    Patent number: 11548941
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: January 10, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xuejun Liu, Ernesto Munoz, Bruce Randazzo
  • MATERIALS AND METHODS FOR INFLAMMATORY MOLECULAR MARKERS
    Publication number: 20230003719
    Abstract: A method of determining a pharmacodynamics or pharmacokinetic effect of an inhibitor of IL 1? comprising providing a sample from a subject; administering the inhibitor of IL 1? to the sample; measuring levels of one or more biomarkers in the sample; and determining the pharmacodynamic or the pharmacokinetic effect of the inhibitor of IL 1? based on the levels of the one or more biomarkers.
    Type: Application
    Filed: December 11, 2020
    Publication date: January 5, 2023
    Inventors: Ernesto MUNOZ, Julianty ANGSANA, Carl MANTHEY, Xuejun LIU
  • SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIS WITH ANTI-IL-23 SPECIFIC ANTIBODY
    Publication number: 20220289835
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
    Type: Application
    Filed: May 2, 2022
    Publication date: September 15, 2022
    Inventors: Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xeujun Liu, Ernesto Munoz, Bruce Randazzo
  • Safe and Effective Method of Treating Psoriasis with Anti-IL-23 Specific Antibody
    Publication number: 20200157209
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g.
    Type: Application
    Filed: November 19, 2019
    Publication date: May 21, 2020
    Inventors: Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xuejun Liu, Ernesto Munoz, Bruce Randazzo